News
10-03-2010, 10:12 PM
Array BioPharma Inc. today announced positive interim results of its novel, oral HER2 (ErbB2) inhibitor, ARRY-380, in a Phase 1 trial in patients with advanced cancer.
More... (http://www.news-medical.net/news/20101004/Array-BioPharma-to-present-positive-interim-results-of-Phase-1-ARRY-380-trial-at-ASCO-Symposium.aspx)
More... (http://www.news-medical.net/news/20101004/Array-BioPharma-to-present-positive-interim-results-of-Phase-1-ARRY-380-trial-at-ASCO-Symposium.aspx)